The Link Between Manufacturing and Commercialization in Gene and Cell Therapies
The highly customized nature of cell and gene therapy production means that manufacturing innovations for one therapy may not be easily transferable to others.
Now that the first cell and gene therapies have become commercial realities and more companies are involved in precision medicine research, different manufacturing platforms are being developed. However, as the authors write, developers need to consider the fundamental differences between these therapies and more traditional biopharmaceuticals to develop the right commercialization strategies.
Read this article in Pharmaceutical Technology’s Biologics and Sterile Drug Manufacturing 2019 eBook.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing 2019
May 2019
Pages: 30–35
Citation
When referring to this article, please cite it as W. Colasante, P. Diesel, and L. Gerlovin, “The Link Between Manufacturing and Commercialization in Gene and Cell Therapies," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2019).
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
